Cost-effectiveness of treatment strategies for rheumatoid arthritis patients with inadequate response to methotrexate

被引：0
|
作者：
Patel, VD [1 ]
Hay, J [1 ]
机构：
[1] Univ So Calif, Los Angeles, CA 90089 USA
来源：
VALUE IN HEALTH | 2004年 / 7卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)62130-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：241 / 241
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of adalimumab (Humira™) in the treatment of US patients with rheumatoid arthritis (RA)
    Bansback, N
    Brennan, A
    Sengupta, N
    VALUE IN HEALTH, 2004, 7 (03) : 241 - 241
  • [42] Cost-effectiveness analysis of etanercept monotherapy versus infliximab plus methotrexate in the treatment of rheumatoid arthritis.
    Malone, DC
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S322 - S322
  • [43] COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM
    Purcaru, O.
    Taylor, P. C.
    Emery, P.
    Palmer, S.
    VALUE IN HEALTH, 2010, 13 (07) : A310 - A310
  • [44] The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis
    Wailoo, Allan
    Hock, Emma S.
    Stevenson, Matt
    Martyn-St James, Marrissa
    Rawdin, Andrew
    Simpson, Emma
    Wong, Ruth
    Dracup, Naila
    Scott, David L.
    Young, Adam
    HEALTH TECHNOLOGY ASSESSMENT, 2017, 21 (71) : 1 - +
  • [45] The efficacy and safety of abatacept or infliximab in patients with rheumatoid arthritis and an inadequate response to methotrexate
    Dougados, M.
    Keiserman, M.
    Codding, C.
    Songcharoen, S.
    Berman, A.
    Nayiager, S.
    Saldate, C.
    Becker, J. C.
    Li, T.
    Schiff, M.
    RHEUMATOLOGY, 2008, 47 : II14 - II15
  • [46] THE COST-EFFECTIVENESS OF LIVER-BIOPSY (BX) IN RHEUMATOID-ARTHRITIS (RA) PATIENTS ON METHOTREXATE (MTX)
    BERGQUIST, SR
    FELSON, DT
    FREEDBERG, KA
    ARTHRITIS AND RHEUMATISM, 1993, 36 (09): : S63 - S63
  • [47] Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
    SiNi Li
    JianHe Li
    LiuBao Peng
    YaMin Li
    XiaoMin Wan
    Rheumatology and Therapy, 2021, 8 : 863 - 876
  • [48] Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
    Li, SiNi
    Li, JianHe
    Peng, LiuBao
    Li, YaMin
    Wan, XiaoMin
    RHEUMATOLOGY AND THERAPY, 2021, 8 (02) : 863 - 876
  • [49] THE COST-EFFECTIVENESS OF LIVER-BIOPSY (BX) IN RHEUMATOID-ARTHRITIS (RA) PATIENTS ON METHOTREXATE (MTX)
    BERGQUIST, SR
    FELSON, DT
    FREEDBERG, KA
    ARTHRITIS AND RHEUMATISM, 1993, 36 (05): : R32 - R32
  • [50] Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
    Alex Diamantopoulos
    A. Finckh
    T. Huizinga
    D. K. Sungher
    L. Sawyer
    D. Neto
    F. Dejonckheere
    PharmacoEconomics, 2014, 32 : 775 - 787
12345